CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
Natsagdorj A, Izumi K, Hiratsuka K, Machioka K, Iwamoto H, Naito R, Makino T, Kadomoto S, Shigehara K, Kadono Y, Lin WJ, Maolake A, Mizokami A.
Natsagdorj A, et al. Among authors: naito r.
Cancer Sci. 2019 Jan;110(1):279-288. doi: 10.1111/cas.13876. Epub 2018 Dec 7.
Cancer Sci. 2019.
PMID: 30426599
Free PMC article.